Zobrazeno 1 - 10
of 16
pro vyhledávání: '"Alex R. Rinehart"'
Autor:
Adeola Adeyeye, Myron S. Cohen, Namandjé N. Bumpus, Sue Li, Halima Dawood, Craig W. Hendrix, Alex R. Rinehart, Irene Kuo, Mina C. Hosseinipour, Joseph S Eron, Albert Y. Liu, Gordon Chau, Ravindre Panchia, Raphael J. Landovitz, Herana Kamal Seneviratne, Allyson N. Hamlin, Marybeth McCauley, Leslie Cottle, Beatriz Grinsztejn
Publikováno v:
ACS Pharmacology & Translational Science
ACS pharmacology & translational science, vol 4, iss 1
ACS pharmacology & translational science, vol 4, iss 1
Cabotegravir (CAB) is an integrase strand-transfer inhibitor of HIV that has proven effective for HIV treatment and prevention in a long-acting injectable formulation, typically preceded by an oral formulation lead-in phase. Previous in vitro studies
Autor:
Sue Li, Craig W. Hendrix, Joseph J. Eron, Albert Y. Liu, Mark A. Marzinke, Paul G. Richardson, Alex R. Rinehart, Marybeth McCauley, Adeola Adeyeye, Susan H. Eshleman, Gordon Chau, Manya Magnus, Beatriz Grinsztejn, Ravindre Panchia, Raphael J. Landovitz, David N. Burns, Halima Dawood, Ryan Kofron, Myron S. Cohen, Leslie Cottle, David Margolis, Mina C. Hosseinipour
Publikováno v:
The Lancet HIV. 7:e472-e481
Summary Background Long-acting injectable cabotegravir is a novel integrase inhibitor currently in advanced clinical development for HIV prevention and treatment. We aimed to assess the terminal phase pharmacokinetics and safety of long-acting inject
Autor:
Philip Sullivan, Adeola Adeyeye, Jeanne M. Marrazzo, James F. Rooney, David J. Margolis, Susan H. Eshleman, Jonathan Lucas, Suwat Chariyalertsak, Ha V Tran, Peter J. Anderson, Hyman M. Scott, Eric S. Daar, Nittaya Phanuphak, Beatriz Grinsztejn, Colleen F Kelley, Craig W. Hendrix, Jorge A Gallardo-Cartagena, J Valdez Madruga, Sheldon D. Fields, Aditya H Gaur, Joseph J. Eron, Myron S. Cohen, Christina Psaros, Paul G. Richardson, Kailazarid Gomez-Feliciano, Zhe Wang, Meredith E. Clement, Timothy H. Holtz, Alex R. Rinehart, Aida Asmelash, Steven A. Safren, Lara E. Coelho, Juan C Hinojosa, Roy M. Gulick, Hptn (PopART) Study Team, Eileen F. Dunne, Andrea Jennings, Javier Valencia Huamaní, Pedro Gonzales, Shobha Swaminathan, Kimberly Y. Smith, Estelle Piwowar-Manning, Deborah Donnell, Marcelo H. Losso, Marcus Bryan, Ryan Kofron, Esper G Kallas, Brett Hanscom, Leslie Cottle, Marybeth McCauley, Jeremy Sugarman, Carlos del Rio, Raphael J. Landovitz, Robinson Cabello, William Spreen, Cheryl Blanchette, Edgar T. Overton, Omar Sued, Katherine Shin, Maoji Li, Keren Middelkoop, Nirupama Sista, Mark A. Marzinke, Breno Santos, Ian Frank, Todd T. Brown
Publikováno v:
The New England journal of medicine, vol 385, iss 7
BackgroundSafe and effective long-acting injectable agents for preexposure prophylaxis (PrEP) for human immunodeficiency virus (HIV) infection are needed to increase the options for preventing HIV infection.MethodsWe conducted a randomized, double-bl
Autor:
Marybeth McCauley, Susan H. Eshleman, Vanessa Cummings, Christos J. Petropoulos, Nittaya Phanuphak, Lara E. Coelho, Maoji Li, Keren Middelkoop, Lane R. Bushman, Casey D Haines, Craig W. Hendrix, James F. Rooney, Raphael J. Landovitz, Alex R. Rinehart, Shahnaz Ahmed, Estelle Piwowar-Manning, Adeola Adeyeye, Ryan Kofron, Daniel Pryluka, Beatriz Grinsztejn, Peter L. Anderson, Brett Hanscom, Marty St. Clair, Myron S. Cohen, Jessica M. Fogel, Mark A. Marzinke, Lei Weng, Deborah Persaud, Aditya H. Gaur, Deborah Donnell
Publikováno v:
J Infect Dis
Background The HIV Prevention Trials Network (HPTN) 083 trial demonstrated that long-acting cabotegravir (CAB-LA) was more effective than tenofovir disoproxil fumarate–emtricitabine (TDF/FTC) in preventing human immunodeficiency virus (HIV) in cisg
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7456b763d6a1711fcdefa47fcd620c06
https://europepmc.org/articles/PMC8599849/
https://europepmc.org/articles/PMC8599849/
Autor:
Adeola Adeyeye, Mark A. Marzinke, Sue Li, David Margolis, Paul G. Richardson, Hptn (PopART) Study Team, Cheríe S Blair, Marybeth McCauley, Susan H. Eshleman, Raphael J. Landovitz, Gordon Chau, Leslie Cottle, Alex R. Rinehart, Craig W. Hendrix
Publikováno v:
J Acquir Immune Defic Syndr
Author(s): Blair, Cherie S; Li, Sue; Chau, Gordon; Cottle, Leslie; Richardson, Paul; Marzinke, Mark A; Eshleman, Susan H; Adeyeye, Adeola; Rinehart, Alex R; Margolis, David; McCauley, Marybeth; Hendrix, Craig W; Landovitz, Raphael J; HPTN 077 Study T
Autor:
Marc O. Siegel, Maseko Bertha, J. J. Eron, Hilton Humphries, Sue Li, Marybeth McCauley, Raphael J. Landovitz, David Margolis, Beatriz Grinsztejn, Gordon Chau, Ravindre Panchia, Albert Y. Liu, Andrea Jennings, Leslie Cottle, Sahar Z Zangeneh, Elizabeth E. Tolley, Alex R. Rinehart
Publikováno v:
AIDS and Behavior
Long-acting injectable PrEP could offer an alternative to daily oral PrEP, improve adherence and protection, if found acceptable, safe and effective. HPTN 077 evaluated injectable cabotegravir safety, tolerability and pharmacokinetics among HIV-uninf
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9115ef66fb7f5b42f270a3d965bdc6d2
Autor:
William Spreen, Britt Stancil, Kenneth H. Mayer, Miranda Murray, Alex R. Rinehart, Parul Patel, Robert M. Grant, Ian Frank, David A. Margolis, Martin Markowitz, Susan L. Ford, Krischan J Hudson
Publikováno v:
HIV Clinical Trials. 19:129-138
Cabotegravir (GSK1265744) is an integrase strand transfer inhibitor in development as a long-acting (LA) intramuscular injectable suspension for HIV-1 pre-exposure prophylaxis (PrEP).We report participant outcomes from the phase IIa ECLAIR study rela
Autor:
Hong Van Tieu, Ian Frank, Elizabeth Gould, Richard Elion, William Spreen, Winkler G. Weinberg, Magdalena E. Sobieszczyk, David A. Margolis, Susan L. Ford, Kimberly Y. Smith, Britt Stancil, Robert M. Grant, Chester Fisher, Kenneth H. Mayer, Deborah Goldstein, Joel E. Gallant, Parul Patel, Alex R. Rinehart, Krischan J Hudson, Martin Markowitz
Publikováno v:
The Lancet HIV. 4:e331-e340
Summary Background Cabotegravir (GSK1265744) is an HIV-1 integrase strand transfer inhibitor with potent antiviral activity and a long half-life when administered by injection that prevented simian-HIV infection upon repeat intrarectal challenge in m
Autor:
Sahar Z Zangeneh, Albert Y. Liu, Adeola Adeyeye, Marybeth McCauley, Raphael J. Landovitz, Manya Magnus, Mina C. Hosseinipour, Halima Dawood, Ryan Kofron, Beatriz Grinsztejn, David A. Margolis, Myron S. Cohen, David N. Burns, Judith S. Currier, Alex R. Rinehart, Joseph J. Eron, Gordon Chau, Ravindre Panchia
Publikováno v:
Clin Infect Dis
Studies in human immunodeficiency virus (HIV)–infected individuals suggest excess weight gain with integrase inhibitor–based antiretroviral therapy. The HIV Prevention Trials Network Study 077 evaluated changes in weight and fasting metabolic par
Autor:
David Margolis, Leslie Cottle, Susan H. Eshleman, Albert Y. Liu, Manya Magnus, Craig W. Hendrix, Beatriz Grinsztejn, Mark A. Marzinke, Alex R. Rinehart, David N. Burns, Myron S. Cohen, Joseph J. Eron, Gordon Chau, Ravindre Panchia, Mina C. Hosseinipour, Adeola Adeyeye, Paul G. Richardson, Sue Li, Marybeth McCauley, Raphael J. Landovitz, Halima Dawood, Ryan Kofron
Publikováno v:
SSRN Electronic Journal.
Background: Long-acting injectable cabotegravir (CAB LA) is a novel integrase inhibitor in advanced clinical development for HIV treatment and HIV prevention. We investigated the terminal pharmacokinetics and safety of CAB LA after final injection as